← Human Trials & Peer-Reviewed Studies
The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.
Plain-language guide to PMID 20421332 (2010): double-blind randomized controlled trial of Growth Hormone.
Key Facts
- PMID
- 20421332
- Journal
- European journal of endocrinology
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Holt RI et al. (9 authors)
- DOI
- 10.1530/EJE-09-0978
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Growth Hormone, published as a randomized controlled trial.
As previous studies involved predominantly white European athletes, it is important to assess whether the response of these markers to recombinant human GH (rhGH) differs with ethnicity.
To examine the response of serum IGF1 and P-III-P and GH-2000 score to rhGH in non-Caucasian amateur athletes.
Why It Was Studied
The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH.
Who Took Part
PubMed indexes the participants as teenagers, young adults and adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Growth Hormone and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Growth Hormone.
Some participants received a placebo instead of Growth Hormone, giving a reference point.
Double-blind placebo-controlled rhGH administration study.
Wellcome Trust Clinical Research Facility, Southampton General Hospital.
The study included 31 male and 14 female amateur athletes of different ethnicities.
Serum IGF1 and P-III-P were measured, and GH-2000 score was calculated.
What Was Measured
PubMed files the paper under topics including Athletes, Collagen Type III, Doping in Sports, Growth Hormone, Insulin-Like Growth Factor I, Placebo Effect and Racial Groups.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Growth Hormone.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2010 (European journal of endocrinology), a journal based in England.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.